149 related articles for article (PubMed ID: 25788219)
61. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
[TBL] [Abstract][Full Text] [Related]
62. Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection.
Hayashi T; Tamori A; Nishikawa M; Morikawa H; Enomoto M; Sakaguchi H; Habu D; Kawada N; Kubo S; Nishiguchi S; Shiomi S
Liver Int; 2009 Jan; 29(1):126-32. PubMed ID: 18492017
[TBL] [Abstract][Full Text] [Related]
63. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
64. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
[TBL] [Abstract][Full Text] [Related]
65. Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Hepatol Res; 2017 Sep; 47(10):1021-1031. PubMed ID: 27859993
[TBL] [Abstract][Full Text] [Related]
66. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.
Li DK; Chung RT
Cancer; 2015 Sep; 121(17):2874-82. PubMed ID: 26079399
[TBL] [Abstract][Full Text] [Related]
67. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
68. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
69. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.
El-Serag HB; Kanwal F; Richardson P; Kramer J
Hepatology; 2016 Jul; 64(1):130-7. PubMed ID: 26946190
[TBL] [Abstract][Full Text] [Related]
70. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC; Aikata H; Katamura Y; Azakami T; Kawaoka T; Saneto H; Uka K; Mori N; Takaki S; Kodama H; Waki K; Imamura M; Shirakawa H; Kawakami Y; Takahashi S; Chayama K
World J Gastroenterol; 2007 Oct; 13(40):5343-50. PubMed ID: 17879404
[TBL] [Abstract][Full Text] [Related]
71. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.
Petta S; Di Marco V; Bruno S; Enea M; Calvaruso V; Boccaccio V; Rossi S; Craxì A; Cammà C
Liver Int; 2016 Dec; 36(12):1765-1773. PubMed ID: 27164508
[TBL] [Abstract][Full Text] [Related]
72. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
73. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
74. Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy.
Tanaka S; Tamori A; Takemura S; Hamano G; Ito T; Kawada N; Kubo S
Am Surg; 2017 Nov; 83(11):1246-1255. PubMed ID: 29183527
[TBL] [Abstract][Full Text] [Related]
75. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.
Di Marco V; Calvaruso V; Ferraro D; Bavetta MG; Cabibbo G; Conte E; Cammà C; Grimaudo S; Pipitone RM; Simone F; Peralta S; Arini A; Craxì A
Gastroenterology; 2016 Jul; 151(1):130-139.e2. PubMed ID: 27039970
[TBL] [Abstract][Full Text] [Related]
76. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
77. Serum MicroRNA-122 and MicroRNA-155: Markers of Disease Progression in Hepatitis C viral infection.
Sheneef A; Gouda AM; Mohammad AN; Yousef LM; Noureldin AK
Egypt J Immunol; 2017 Jun; 24(2):33-46. PubMed ID: 29528577
[TBL] [Abstract][Full Text] [Related]
78. Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma.
Sugimachi K; Araki H; Saito H; Masuda T; Miura F; Inoue K; Shimagaki T; Mano Y; Iguchi T; Morita M; Toh Y; Yoshizumi T; Ito T; Mimori K
JGH Open; 2022 Dec; 6(12):854-863. PubMed ID: 36514506
[TBL] [Abstract][Full Text] [Related]
79. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.
Kanogawa N; Ogasawara S; Chiba T; Saito T; Motoyama T; Suzuki E; Ooka Y; Tawada A; Kanda T; Mikami S; Azemoto R; Kaiho T; Shinozaki M; Ohtsuka M; Miyazaki M; Yokosuka O
J Gastroenterol Hepatol; 2015 Jul; 30(7):1197-204. PubMed ID: 25682720
[TBL] [Abstract][Full Text] [Related]
80. Characterization of circulating miRNAs in the treatment of primary liver tumors.
Umezu T; Tanaka S; Kubo S; Enomoto M; Tamori A; Ochiya T; Taguchi YH; Kuroda M; Murakami Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1964. PubMed ID: 38146079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
